Retatrutide: the triple agonist that may reset the ceiling.

Retatrutide (development code LY3437943) is a synthetic peptide engineered by Eli Lilly to activate three receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. It is dosed by once-weekly subcutaneous injection, in the same delivery format as tirzepatide and semaglutide.

If approved at the doses Phase 2 evaluated (8 mg and 12 mg), retatrutide would offer the highest weight-loss potential of any incretin-class drug. The Phase 2 data published in the New England Journal of Medicine in June 2023 — 24.2% mean body weight loss at 48 weeks at 12 mg — set the new expectations bar that the Phase 3 TRIUMPH program is now being measured against.

Each of the three receptors retatrutide activates does something different to body weight regulation:

The bet — borne out by Phase 2 data — is that combining all three pathways produces additive effects rather than redundant ones. GLP-1 alone (Wegovy) tops out around 15% body weight loss; GLP-1 + GIP (Zepbound) reaches ~21%; GLP-1 + GIP + glucagon (retatrutide) reached ~24% in Phase 2. The shape of the dose-response curve in Phase 2 also suggests higher doses than 12 mg might extract still more benefit — Phase 3 will test the upper bound.

The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with BMI ≥30 (or ≥27 with comorbidities) without diabetes. Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (with two different titration schedules), 8 mg, or 12 mg.

• 1 mg dose: ~7.2% body weight loss at 48 weeks
• 4 mg dose: ~12.9–17.5% body weight loss depending on titration
• 8 mg dose: ~22.1% body weight loss
• 12 mg dose: 24.2% body weight loss
• Placebo: 2.1% body weight loss

A separate Phase 2 trial in adults with type 2 diabetes (Rosenstock et al., Lancet 2023) showed A1c reductions of up to 2.16 percentage points at 36 weeks at the highest dose, alongside meaningful weight loss — important because tirzepatide and semaglutide both deliver smaller percentage weight losses in T2D populations than in non-diabetic obesity populations.

Lilly is running retatrutide through the TRIUMPH Phase 3 program across multiple indications:

• TRIUMPH-1, TRIUMPH-2, TRIUMPH-3: obesity pivotal trials (different durations and populations)
• TRIUMPH-4: type 2 diabetes
• TRIUMPH-5: obesity with established cardiovascular disease
• TRIUMPH-OSA: obstructive sleep apnea in obesity
• TRIUMPH-MASH: metabolic dysfunction-associated steatohepatitis (formerly NASH)
• TRIUMPH knee OA: knee osteoarthritis in obesity

Topline obesity data from TRIUMPH-1 is expected in early 2026; if positive and consistent with Phase 2, an FDA submission could land later in 2026 with a potential approval decision in late 2026 or early 2027. Lilly has indicated that the cardiovascular outcomes trial (TRIUMPH-5) will read out later, similar to how SELECT followed the initial semaglutide approvals.

Putting the data on the same scale — recognizing these are not head-to-head trials, just the headline efficacy figures from each pivotal program:

The pattern is clear: each generation has added roughly a 5-percentage-point improvement in mean weight loss over its predecessor. Retatrutide’s Phase 3 data will confirm or break that trajectory.

One caveat: the percentages are meanvalues. The spread within each trial is wide. Tirzepatide’s 15 mg arm in SURMOUNT-1 had patients achieving anywhere from 5% to 30%+ weight loss. Retatrutide is likely to show the same heterogeneity. The drug that produces the highest mean may not be the highest-responding drug for any given individual.

Phase 2 side effects looked similar in pattern to tirzepatide and semaglutide: nausea, diarrhea, and vomiting were the most common, dose-related, and concentrated during titration. By the maintenance phase, most patients were tolerating their dose without ongoing GI symptoms.

Glucagon receptor activation introduces a few specific things to monitor:

• Heart rate: Phase 2 saw small increases in resting heart rate (about 5–8 beats per minute on average, dose-related). Whether this remains within clinically acceptable bounds at scale is a Phase 3 question.
• LDL cholesterol: Modest increases were observed at the highest dose. The clinical significance alongside the metabolic improvements is being tracked.
• Hyperglycemia in non-diabetics: Glucagon raises blood sugar, but the GLP-1 and GIP components of retatrutide largely offset this. Phase 2 fasting glucose was actually lower in retatrutide arms than placebo in the obesity study.

The Phase 3 program’s size will provide the definitive safety picture. Boxed warnings consistent with the GLP-1 class (thyroid C-cell tumor signal in rodents, pancreatitis, gallbladder events) are expected.

Best-case timeline:

• Q1–Q2 2026: First TRIUMPH Phase 3 topline readouts (obesity)
• Q3–Q4 2026: FDA submission, assuming positive data
• Late 2026 to 2027: FDA decision under standard review timelines
• 2027 onward: Commercial launch, payer coverage build-out

Pricing has not been announced. List price will likely anchor in the same $1,000–$1,200 monthly range as tirzepatide. The more meaningful access question is payer coverage: Medicare’s evolving approach to obesity drugs (now expanded for cardiovascular and OSA indications) and commercial-plan formulary decisions will determine real-world out-of-pocket cost more than list price will.

Compounded retatrutide is not currently a legal pathway — a drug must be on the FDA shortage list for compounding under sections 503A/503B, and retatrutide isn’t approved at all yet.